Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Oncology Consultations™: How Do The Experts Utilize PARP Inhibitors in Ovarian Cancer Across Lines of Care?

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Activity Overview

This Oncology Consultations^TM is a video-based program in which 2 experts use a case-based approach to discuss the utility of PARP inhibitors in the treatment and management of ovarian cancer. In this activity the faculty focus on biomarker testing, current therapeutic strategies for the management of ovarian cancer across lines of care, and evidence-based management of treatment-related adverse events. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of ovarian cancer and to improve outcomes for their patients with this disease.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, gynecologic oncologists, surgical oncologists, and other physicians who treat patients with ovarian cancer. Nurses, nurse practitioners, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of ovarian cancer will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Analyze evidence from clinical trials that have evaluated PARP inhibitors for patients with ovarian cancer across lines of care
Explain the rationale for PARP inhibitor-based strategies to personalize care in the maintenance setting
Understand the role of molecular testing and its application in selecting therapy for patients with ovarian cancer
Apply strategies for the recognition and management of adverse events associated with PARP inhibitors and other agents in ovarian cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

Faculty

Kathleen N. Moore, MD, MS
Virginia Kerley Cade Chair in Cancer Clinical Trials
Associate Director, Clinical Research
Director Phase 1 Clinical Research
Stephenson Cancer Center
Oklahoma City, OK

Disclosures: Grant/Research Support: PTC Therapeutics, Lilly, Merck, GSK/Tesaro, Verastem Oncology. Consultant: Astra Zeneca, GSK, I-Mab Biopharma, Amgen. Other Support: Advisory boards: Alkermes, AstraZeneca, Aravive, Blueprint Medicines, Eisai Co., Elevar Therapeutics, GSK/Tesaro, Genentech/Roche, Jiangsu Hengrui Pharmacuticals, I-Mab Biopharma, ImmunoGen, EQRx, Mereo, Mersana Therapeutics, Merck, Myriad Genetics, Novartis, OncXerna Therapeutics, Onconova Therapeutics, Sorrento Therapeutics, Tarveda Therapeutics, VBL Therapeutics.

Ritu Salani MD, MBA
Professor
Department of Obstetrics/Gynecology
University of California Los Angeles
Los Angeles, CA

Disclosures: Consultant: GSK, Merck, Instil Bio, Arcus Biosciences, Seagen, Regeneron, Genentech.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.